Clinical trials
Phase 2 Liver Diseases trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Terminated | 4 |
| Active, not recruiting | 3 |
| Recruiting | 2 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Genfit | 2 |
| Mirum Pharmaceuticals, Inc. | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| AusperBio Therapeutics Inc. | 1 |
| Boehringer Ingelheim | 1 |
| Boston Scientific Corporation | 1 |
| Bristol-Myers Squibb | 1 |
| Debiopharm International SA | 1 |
| Enyo Pharma | 1 |
| European Foundation for Study of Chronic Liver Failure | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Liver Diseases | 18 |
| Digestive System Diseases | 5 |
| Fibrosis | 5 |
| Non-alcoholic Fatty Liver Disease | 5 |
| Carcinoma, Hepatocellular | 3 |
| Acute-On-Chronic Liver Failure | 2 |
| Adenocarcinoma | 2 |
| Bile Duct Diseases | 2 |
| Biliary Tract Diseases | 2 |
| Carcinoma | 2 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.